ABSTRACT
PURPOSE: To prospectively evaluate the short-term toxicoses associated with pegylated-liposomal doxorubicin (Doxil) administered to dogs with measurable tumors of various histologic types and sites. Preliminary information regarding efficacy was also generated. METHODS: A group of 51 dogs with histologically confirmed malignancies received a total of 103 Doxil treatments given i.v. every 3 weeks at dosages ranging from 0.75 to 1.1 mg/kg in the context of a phase I dose-escalation trial. Acute and short-term toxicities as well as tumor response and duration of response were characterized. RESULTS: The maximally tolerated dose in tumor-bearing dogs was established as 1.0 mg/kg i.v. every 3 weeks. The dose-limiting toxicity was a cutaneous toxicity clinically resembling palmar-plantar erythrodysesthesia (PPES). An overall response rate of 25.5% was observed with five complete responders and eight partial responders. CONCLUSIONS: Doxil appeared to be well tolerated at dosages similar to those tolerated for free doxorubicin in tumor-bearing dogs. PPES was the dose-limiting toxicity encountered, rather than myelosuppresion as is the case with free doxorubicin in dogs. Doxil as a single agent may have a broad spectrum of activity and deserves further evaluation.
Subject(s)
Antibiotics, Antineoplastic/administration & dosage , Dog Diseases , Doxorubicin/administration & dosage , Neoplasms/veterinary , Animals , Antibiotics, Antineoplastic/therapeutic use , Antibiotics, Antineoplastic/toxicity , Dogs , Doxorubicin/therapeutic use , Doxorubicin/toxicity , Drug Carriers , Female , Gastrointestinal Diseases/chemically induced , Gastrointestinal Diseases/veterinary , Liposomes , Male , Neoplasms/drug therapy , Neoplasms/pathology , Orchiectomy , Ovariectomy , Prospective Studies , Skin/drug effects , Skin/pathologyABSTRACT
OBJECTIVE: To determine for mast cell tumors in dogs whether frequency of argyrophilic nucleolar organizer regions (AgNOR) determined by examining fine-needle aspirates (FNA) correlated with frequencies determined by examining biopsy specimens or with histologic grade. DESIGN: Case series. ANIMALS: 25 dogs with 32 histologically confirmed tumors. PROCEDURE: Biopsy specimens and FNA were collected from each tumor. Histologic grade and AgNOR frequency were determined. RESULTS: Frequency of AgNOR in FNA was significantly correlated with frequency in biopsy specimens and was significantly associated with histologic grade of the tumor. CLINICAL IMPLICATIONS: Determining AgNOR frequency in FNA of mast cell tumors in dogs is a rapid, minimally invasive means of obtaining information that potentially could be used to help predict biological behavior of the tumor and to guide clinicians and owners in making decisions about further diagnostic tests and treatment.
